<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Auclair M</submitter><funding>ViiV Healthcare</funding><pagination>e0226924</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6977740</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(1)</volume><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Aging HIV-infected antiretroviral-treatment (ART)-controlled patients often present cardiovascular and metabolic comorbidities. Thus, it is mandatory that life-long used ART has no cardiometabolic toxicity. Protease inhibitors have been associated with cardiometabolic risk, integrase-strand-transfer-inhibitors (INSTI) with weight gain and the CCR5 inhibitor maraviroc with improved vascular function. We have previously reported that the INSTI dolutegravir and maraviroc improved, and ritonavir-boosted atazanavir(atazanavir/r) worsened, inflammation and senescence in human coronary artery endothelial cells (HCAEC)s from adult controls. Here, we analyzed the pathways involved in the drugs' effects on inflammation, senescence and also insulin resistance.&lt;h4>Methods&lt;/h4>We ana</pubmed_abstract><journal>PloS one</journal><pubmed_title>HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.</pubmed_title><pmcid>PMC6977740</pmcid><funding_grant_id>research grant paid to Sorbonne University</funding_grant_id><pubmed_authors>Capeau J</pubmed_authors><pubmed_authors>Fellahi S</pubmed_authors><pubmed_authors>Guenantin AC</pubmed_authors><pubmed_authors>Auclair M</pubmed_authors><pubmed_authors>Garcia M</pubmed_authors></additional><is_claimable>false</is_claimable><name>HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.</name><description>&lt;h4>Objectives&lt;/h4>Aging HIV-infected antiretroviral-treatment (ART)-controlled patients often present cardiovascular and metabolic comorbidities. Thus, it is mandatory that life-long used ART has no cardiometabolic toxicity. Protease inhibitors have been associated with cardiometabolic risk, integrase-strand-transfer-inhibitors (INSTI) with weight gain and the CCR5 inhibitor maraviroc with improved vascular function. We have previously reported that the INSTI dolutegravir and maraviroc improved, and ritonavir-boosted atazanavir(atazanavir/r) worsened, inflammation and senescence in human coronary artery endothelial cells (HCAEC)s from adult controls. Here, we analyzed the pathways involved in the drugs' effects on inflammation, senescence and also insulin resistance.&lt;h4>Methods&lt;/h4>We ana</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020</publication><modification>2026-05-07T01:46:23.567Z</modification><creation>2020-05-22T09:48:14Z</creation></dates><accession>S-EPMC6977740</accession><cross_references><pubmed>31971958</pubmed><doi>10.1371/journal.pone.0226924</doi></cross_references></HashMap>